Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Recenti Prog Med ; 102(7-8): 307-9, 2011.
Article in Italian | MEDLINE | ID: mdl-21779124

ABSTRACT

Schwannomas are degenerate peripheral nerve sheath tumors that very rarely occur in the retroperitoneum. They are usually benign than malignancy is very rare and is usually observed in patients with von Recklinghausen disease. We report a case of female adult patient who presented with vague abdominal discomfort. The preoperative diagnosis was difficult and the treatment was complete surgical excision. The patient is with no evidence of recurrence more than four years after surgery.


Subject(s)
Neurilemmoma , Retroperitoneal Neoplasms , Female , Humans , Middle Aged , Neurilemmoma/diagnosis , Retroperitoneal Neoplasms/diagnosis
2.
Front Biosci ; 11: 1275-9, 2006 May 01.
Article in English | MEDLINE | ID: mdl-16368513

ABSTRACT

UNLABELLED: The purpose of this phase II trial was to assess tolerance and efficacy of the combination of radiation, fluorouracil and oxaliplatin as neoadjuvant treatment in locally advanced rectal cancer. Between March 2001 and August 2004 , 28 patients M/18 F/10 with locally advanced rectal cancer were entered in our study. All the patients underwent to the Radiotherapy with a total dose was 45 Gy and concurrent chemotherapy with Oxaliplatin 80 mg/mq G1 on weeks 1,3,5 followed by five day continuous infusion of 5-Fluorouracile 300 mg/mq on five consecutive weeks. Surgery was planned 5 weeks later. Surgery was performed in all patients after a mean interval time of 5 weeks. Side effects and toxicity included grade II sec WHO diarrhea and grade II mucositis , grade I-II dysuria and skin reaction Downstaging to T0-2N0 was achieved in 18 patients (65%) with 4 (15%) achieving a pathologically complete response. CONCLUSIONS: Such a combined preoperative chemioradiotherapy and oxaliplatin-containing regimen is well tolerated with non increase in surgical toxicity. The good response rate observed warrants its use in further clinical trials.


Subject(s)
Adenocarcinoma/therapy , Antineoplastic Agents/administration & dosage , Combined Modality Therapy/methods , Organoplatinum Compounds/administration & dosage , Rectal Neoplasms/therapy , Adenocarcinoma/drug therapy , Adenocarcinoma/radiotherapy , Adenocarcinoma/surgery , Adult , Aged , Chemotherapy, Adjuvant , Clinical Trials as Topic , Dose-Response Relationship, Drug , Dose-Response Relationship, Radiation , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Oxaliplatin , Radiotherapy Dosage , Rectal Neoplasms/drug therapy , Rectal Neoplasms/radiotherapy , Rectal Neoplasms/surgery , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...